Roche is set to release more data on safety and tolerability at the European Association for the Study of Diabetes (EASD) conference, which is expected to impact stock volatility. Roche has seen a 23% increase in share price following the release of obesity data, with nausea and vomiting rates expected in the regions of 20-40% and 10-30%. However, sentiment has shifted negatively as detailed data is anticipated. Roche will hold an investor event on September 13th, 2024, at 4 pm UK/5 pm CET. In addition, Roche is advancing AI-driven cancer diagnostics by expanding its digital pathology open environment through a collaboration with Stratipath, which will provide distribution rights to the Stratipath Breast solution. This expansion integrates over 20 AI algorithms from eight new collaborators.